In a recent Phase II trial involving 35 patients with tumors with AKT mutations capivasertib, an AKT inhibitor, has demonstrated signs of effectiveness.
Scientists have discovered a new computer software system that can be utilized in order to forecast how certain cancers may respond to a new drug even before it has been given to patients.
A recent study published in JCO Precision Oncology provides new insights into the pathobiology of NF1 mutant GISTs. Demonstrating the potential of genomically driven precision oncology care in the implementation of personalized treatments and counselling for patients with GISTs.
Novel technology, using single-color digital PCR, could enable the detection of cancerous DNA in circulating blood.
Putting cancers’ vulnerabilities on the map: Cancer Dependency Map unveils potential treatment targets
Researchers have unveiled the first draft of a genome-wide cancer ‘dependency map’; the map reveals more than 760 genetic dependencies across multiple cancers.
In this interview, Illumina’s Chief Scientist, David Bentley, speaks about the 100,000 Genomes Project which could transform the way cancer patients are cared for.
Targeted sequencing focused on cancer-related genes provides comprehensive assessment of tumor mutational burden, with results comparable to whole-exome sequencing.
NGS-guided assessment of interactions between tumors and the immune system leads to new discoveries…
In this editorial from Future Oncology the different types of endometrial cancer are appraised.
A commentry of brain tumors associated with Li-Fraumeni syndrome, followed by a case report of the development of a rare gliosarcoma in a Li-Fraumeni patient